You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

CITALOPRAM HYDROBROMIDE Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Citalopram Hydrobromide patents expire, and what generic alternatives are available?

Citalopram Hydrobromide is a drug marketed by Almatica, Mylan Pharms Inc, Aurobindo Pharma, Chartwell Molecular, Hetero Labs Ltd Iii, Hikma, Pharm Assoc, Biovail Labs Intl, Amneal Pharms Ny, Apotex, Aurobindo, Cosette, Dr Reddys Labs Ltd, Epic Pharma, Epic Pharma Llc, Fosun Pharma, Glenmark Generics, Heritage Pharma, Invagen Pharms, Jubilant Generics, Mylan, Natco Pharma Ltd, Roxane, Sun Pharm Inds Inc, Sun Pharm Industries, Taro, and Torrent Pharms. and is included in thirty-four NDAs.

The generic ingredient in CITALOPRAM HYDROBROMIDE is citalopram hydrobromide. There are fifty-six drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the citalopram hydrobromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Citalopram Hydrobromide

A generic version of CITALOPRAM HYDROBROMIDE was approved as citalopram hydrobromide by AUROBINDO on October 28^th, 2004.

Try a Trial

Summary for CITALOPRAM HYDROBROMIDE

US Patents:	0
Applicants:	27
NDAs:	34
Finished Product Suppliers / Packagers:	43
Raw Ingredient (Bulk) Api Vendors:	132
Clinical Trials:	12
Patent Applications:	1,781
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for CITALOPRAM HYDROBROMIDE
Drug Sales Revenues:	Drug sales revenues for CITALOPRAM HYDROBROMIDE
DailyMed Link:	CITALOPRAM HYDROBROMIDE at DailyMed

Drug patent expirations by year for CITALOPRAM HYDROBROMIDE

Drug Prices for CITALOPRAM HYDROBROMIDE

Recent Clinical Trials for CITALOPRAM HYDROBROMIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 3
Haining Health-Coming Biotech Co., Ltd.	Phase 2
Alphacait, LLC	Phase 2

See all CITALOPRAM HYDROBROMIDE clinical trials

Pharmacology for CITALOPRAM HYDROBROMIDE

Drug Class	Serotonin Reuptake Inhibitor
Mechanism of Action	Serotonin Uptake Inhibitors

Medical Subject Heading (MeSH) Categories for CITALOPRAM HYDROBROMIDE

Antidepressive Agents, Second-Generation
Serotonin Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for CITALOPRAM HYDROBROMIDE

N06AB	Selective serotonin reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for CITALOPRAM HYDROBROMIDE

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan Pharms Inc	CITALOPRAM HYDROBROMIDE	citalopram hydrobromide	TABLET;ORAL	077037-003	Nov 5, 2004		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Fosun Pharma	CITALOPRAM HYDROBROMIDE	citalopram hydrobromide	TABLET;ORAL	077035-003	Oct 28, 2004		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Epic Pharma	CITALOPRAM HYDROBROMIDE	citalopram hydrobromide	TABLET;ORAL	077045-002	Apr 29, 2005	AB	RX	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Taro	CITALOPRAM HYDROBROMIDE	citalopram hydrobromide	TABLET;ORAL	077278-003	Mar 22, 2006		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Heritage Pharma	CITALOPRAM HYDROBROMIDE	citalopram hydrobromide	TABLET;ORAL	077232-001	Oct 31, 2005		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Invagen Pharms	CITALOPRAM HYDROBROMIDE	citalopram hydrobromide	TABLET;ORAL	077534-003	Oct 3, 2006	AB	RX	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.